Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 2091
Journal of Gastrointestinal & Digestive System received 2091 citations as per Google Scholar report
Journal of Gastrointestinal & Digestive System peer review process verified at publons
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- China National Knowledge Infrastructure (CNKI)
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Nucleic acid polymers: Broad spectrum antiviral agents and their development as the backbone of new antiviral therapies for the treatment of chronic HBV and HBV/HDV infection
8th International Conference on Clinical Gastroenterology & Hepatology
Andrew Vaillant
Replicor Inc., Canada
Keynote: J Gastrointest Dig Syst
Abstract
Nucleic Acid Polymers (NAPs) are an emerging antiviral technology with broad spectrum activity in a variety of enveloped viruses. Through a novel, sequence independent application of oligonucleotide technology, NAPs are able to interfere with entry and post entry mechanisms in many of the viral infections afflicting humans. The pharmacologic features of NAPs, the mechanistic basis for their broad spectrum antiviral activity and their unique antiviral properties in HBV and HDV infection will be discussed as well as their antiviral effects and ability to synergize with immunotherapy to achieve functional control of infection in completed and ongoing clinical trials in patients with chronic HBV infection and HBV/HDV co-infection.Biography
Andrew Vaillant is the Inventor of Replicor’s NAP technology and has more than 15 years of experience in viral biology, antiviral drug development and nucleic acid chemistry. He has authored numerous publications and patents on the development and use of NAPs as agents to treat infectious diseases. He previously held positions at two Montreal-area biotechnology companies. He was a Post-doctoral fellow at the Montreal Neurological Institute and holds a PhD in Cell Biology from the University of Ottawa.
Email: availlant@replicor.com
